Overview

A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder

Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of once a day ramelteon tablets for sublingual administration (TAK-375SL) in the maintenance treatment of bipolar 1 disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda